Biotechnology company Ochre Bio has completed research into human liver functional genomics and single-cell datasets, following a partnership with GSK. 

Results include a large-scale functional genomics data from research into primary human hepatocytes and a single-cell dataset built from perfused human donor livers. 

Ochre’s research into functional genomics was completed by systematically knocking down all known hepatocyte genes in multiple donors and profiling downstream effects with RNA sequencing. 

Results from donor livers were recorded by capturing gene expression across different cell types and donors. 

The collaboration between Ochre and GSK now transitions into a multi-year co-exclusive license agreement. Both parties have the ability to use Ochre-generated proprietary human liver data to accelerate the discovery and development of new treatments for liver diseases. 

It is hoped that, by revealing how different liver cell populations contribute to liver disease progression, the collaboration could provide foundational data for training AI models, furthering understanding of promising therapeutic targets. 

“To develop therapies that truly impact the lives of liver patients, we cannot compromise on building large-scale human datasets,” said Quin Wills, Founder and CEO of Ochre Bio.  

“Datasets that move beyond population genetics, allowing us to causally explore the complexities of human disease biology. These foundational datasets developed with GSK feed our algorithms (AI) to do just that.” 

“Our collaboration with Ochre has generated data that supports our deepened understanding of human biology and disease,” added Kaivan Khavandi, SVP, Head of Respiratory, Immunology & Inflammation at GSK.  

“This data feeds our AI models and helps power our work to discover and develop new medicines for liver diseases for patients who are waiting.” 

 

Bruno Quinney, Content Team, DDW